EE05124B1 - Toimeainena dotsetakseeli v?i selle hdraati sisaldava kompositsiooni kasutamine - Google Patents

Toimeainena dotsetakseeli v?i selle hdraati sisaldava kompositsiooni kasutamine

Info

Publication number
EE05124B1
EE05124B1 EEP200200087A EEP200200087A EE05124B1 EE 05124 B1 EE05124 B1 EE 05124B1 EE P200200087 A EEP200200087 A EE P200200087A EE P200200087 A EEP200200087 A EE P200200087A EE 05124 B1 EE05124 B1 EE 05124B1
Authority
EE
Estonia
Prior art keywords
docetaxel
drate
composition
active ingredient
hepatocellular carcinoma
Prior art date
Application number
EEP200200087A
Other languages
English (en)
Estonian (et)
Inventor
Chi Chin-Wen
Lin Heng-Liang
Liu Tsung-Yun
Lui Wing-Yiu
Chau Gar-Yang
Original Assignee
Aventis Pharma S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma S.A. filed Critical Aventis Pharma S.A.
Publication of EE200200087A publication Critical patent/EE200200087A/xx
Publication of EE05124B1 publication Critical patent/EE05124B1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
EEP200200087A 1999-08-31 2000-08-29 Toimeainena dotsetakseeli v?i selle hdraati sisaldava kompositsiooni kasutamine EE05124B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9920548.6A GB9920548D0 (en) 1999-08-31 1999-08-31 Treatment of hepatocellular carcinoma
PCT/EP2000/008782 WO2001015675A2 (en) 1999-08-31 2000-08-29 Use of docetaxel for treating hepatocellular carcinoma

Publications (2)

Publication Number Publication Date
EE200200087A EE200200087A (et) 2003-04-15
EE05124B1 true EE05124B1 (et) 2009-02-16

Family

ID=10860081

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200087A EE05124B1 (et) 1999-08-31 2000-08-29 Toimeainena dotsetakseeli v?i selle hdraati sisaldava kompositsiooni kasutamine

Country Status (34)

Country Link
US (2) US20030158249A1 (sr)
EP (1) EP1214061B1 (sr)
JP (1) JP4866522B2 (sr)
KR (1) KR100670416B1 (sr)
CN (1) CN1174748C (sr)
AT (1) ATE269700T1 (sr)
AU (1) AU777583B2 (sr)
BG (1) BG65913B1 (sr)
BR (1) BR0013625A (sr)
CA (1) CA2382294C (sr)
CZ (1) CZ301378B6 (sr)
DE (1) DE60011794T2 (sr)
DK (1) DK1214061T3 (sr)
EA (1) EA004804B1 (sr)
EE (1) EE05124B1 (sr)
ES (1) ES2218223T3 (sr)
GB (1) GB9920548D0 (sr)
HK (1) HK1048944B (sr)
HR (1) HRP20020171A2 (sr)
HU (1) HU228861B1 (sr)
IL (2) IL147489A0 (sr)
ME (1) ME00624B (sr)
MX (1) MXPA02002041A (sr)
NO (1) NO328527B1 (sr)
NZ (1) NZ517604A (sr)
PL (1) PL212612B1 (sr)
PT (1) PT1214061E (sr)
RS (1) RS50148B (sr)
SI (1) SI1214061T1 (sr)
SK (1) SK286378B6 (sr)
TW (1) TW589180B (sr)
UA (1) UA72927C2 (sr)
WO (1) WO2001015675A2 (sr)
ZA (1) ZA200201408B (sr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1268619C (zh) * 2003-05-08 2006-08-09 上海迪赛诺化学制药有限公司 多烯紫杉醇三水化合物的制备方法
WO2005061474A1 (en) * 2003-12-12 2005-07-07 Quiral Química Do Brasil Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions
US7449196B2 (en) * 2004-07-09 2008-11-11 Robert Sabin Anti tumor compositions and methods of use
KR101420445B1 (ko) * 2005-08-31 2014-07-16 아브락시스 바이오사이언스, 엘엘씨 수 난용성 제약학적 약제 및 항균제를 포함하는 조성물
AU2006284657B2 (en) * 2005-08-31 2012-07-19 Abraxis Bioscience, Llc Compositions and methods for preparation of poorly water soluble drugs with increased stability
US9839667B2 (en) 2005-10-14 2017-12-12 Allergan, Inc. Prevention and treatment of ocular side effects with a cyclosporin
US20080081051A1 (en) * 2006-09-28 2008-04-03 Robert Sabin Method of manufacturing anti-tumor and anti-viral compositions
JP2010524919A (ja) * 2007-04-23 2010-07-22 サン、ファーマスーティカル、インダストリーズ、リミテッド 医薬組成物
FR2917088B1 (fr) * 2007-06-08 2009-09-04 Aventis Pharma Sa Dissolution directe du docetaxel dans un solvant dans le polysorbate 80
US8541360B2 (en) * 2008-11-19 2013-09-24 Ben Venue Laboratories, Inc. Parenteral formulations comprising sugar-based esters and ethers
CA3051495A1 (en) 2010-03-26 2011-09-29 Abraxis Bioscience, Llc Use of nanoparticles comprising a taxane and albumin in the treatment of hepatocellular carcinoma
EA027666B1 (ru) * 2010-05-03 2017-08-31 ТЕИКОКУ ФАРМА ЮСЭй, ИНК. Неводные лекарственные средства в форме проэмульсии на основе таксанов и способы их приготовления и использования
US8842114B1 (en) 2011-04-29 2014-09-23 Nvidia Corporation System, method, and computer program product for adjusting a depth of displayed objects within a region of a display
JO3685B1 (ar) * 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US20160250177A1 (en) * 2015-02-17 2016-09-01 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629819B1 (fr) * 1988-04-06 1990-11-16 Rhone Poulenc Sante Procede de preparation de derives de la baccatine iii et de la desacetyl-10 baccatine iii
US5543154A (en) * 1991-12-27 1996-08-06 Merck & Co., Inc. Controlled release nifedipine delivery device
ES2133158T3 (es) * 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
US5846945A (en) * 1993-02-16 1998-12-08 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5436243A (en) * 1993-11-17 1995-07-25 Research Triangle Institute Duke University Aminoanthraquinone derivatives to combat multidrug resistance
FR2718963B1 (fr) * 1994-04-25 1996-05-24 Rhone Poulenc Rorer Sa Nouvelle composition pharmaceutique à base de taxoïdes.
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US5968972A (en) 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
FR2742751B1 (fr) * 1995-12-22 1998-01-30 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
US6503893B2 (en) * 1996-12-30 2003-01-07 Bone Care International, Inc. Method of treating hyperproliferative diseases using active vitamin D analogues
EP0954283B1 (en) * 1996-12-30 2007-03-21 Battelle Memorial Institute Use of a non-encapsulated anticancer drug for the preparation of a formulation for treating neoplasms by inhalation
BRPI9810945B8 (pt) * 1997-06-27 2021-05-25 Abraxis Bioscience Inc formulações de agentes farmacológicos, métodos para sua preparação e métodos para uso das mesmas
ATE233104T1 (de) * 1997-09-18 2003-03-15 Janssen Pharmaceutica Nv Kondensierte imidazolderivate zur erhöhung der oralen bioverfügbarkeit von pharmazeutika
US6576660B1 (en) * 1997-10-31 2003-06-10 Arch Development Corporation Methods and compositions for regulation of 5-α-reductase activity
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
BR9916536A (pt) * 1998-12-23 2002-01-02 Searle & Co Método para o tratamento ou prevenção de um distúrbio de neoplasia em um mamìfero em necessidade deste tratamento ou prevenção, e, combinação
GB9909925D0 (en) * 1999-04-29 1999-06-30 Pharmacia & Upjohn Spa Combined preparations comprising anthracycline derivatives
TW200745026A (en) * 2005-12-13 2007-12-16 Teva Pharma Crystal form of atorvastatin hemi-calcium and processes for preparation thereof

Also Published As

Publication number Publication date
EA200200313A1 (ru) 2002-08-29
AU777583B2 (en) 2004-10-21
EP1214061A2 (en) 2002-06-19
IL147489A0 (en) 2002-08-14
NO328527B1 (no) 2010-03-08
NO20020829D0 (no) 2002-02-20
US20080045584A1 (en) 2008-02-21
CZ2002739A3 (cs) 2002-06-12
CZ301378B6 (cs) 2010-02-03
MEP7809A (en) 2011-12-20
DK1214061T3 (da) 2004-11-01
PL353198A1 (en) 2003-11-03
BG65913B1 (bg) 2010-05-31
HK1048944B (zh) 2005-04-22
SI1214061T1 (en) 2004-12-31
PT1214061E (pt) 2004-09-30
NO20020829L (no) 2002-02-20
ES2218223T3 (es) 2004-11-16
US20030158249A1 (en) 2003-08-21
RS50148B (sr) 2009-05-06
CA2382294A1 (en) 2001-03-08
ZA200201408B (en) 2003-07-30
YU11402A (sh) 2005-07-19
EP1214061B1 (en) 2004-06-23
DE60011794T2 (de) 2005-07-14
KR20020060166A (ko) 2002-07-16
JP4866522B2 (ja) 2012-02-01
WO2001015675A2 (en) 2001-03-08
BG106460A (bg) 2002-09-30
TW589180B (en) 2004-06-01
JP2003508427A (ja) 2003-03-04
KR100670416B1 (ko) 2007-01-17
HUP0203197A3 (en) 2005-01-28
HUP0203197A2 (hu) 2003-01-28
EA004804B1 (ru) 2004-08-26
CN1174748C (zh) 2004-11-10
WO2001015675A3 (en) 2001-09-20
CN1372466A (zh) 2002-10-02
UA72927C2 (uk) 2005-05-16
PL212612B1 (pl) 2012-10-31
GB9920548D0 (en) 1999-11-03
ATE269700T1 (de) 2004-07-15
AU7516800A (en) 2001-03-26
EE200200087A (et) 2003-04-15
HRP20020171A2 (en) 2004-02-29
SK286378B6 (sk) 2008-08-05
CA2382294C (en) 2008-06-03
ME00624B (me) 2011-12-20
HU228861B1 (hu) 2013-06-28
DE60011794D1 (de) 2004-07-29
HK1048944A1 (en) 2003-04-25
MXPA02002041A (es) 2002-08-20
BR0013625A (pt) 2002-05-14
IL147489A (en) 2006-06-11
SK2712002A3 (en) 2002-07-02
NZ517604A (en) 2004-04-30

Similar Documents

Publication Publication Date Title
EE05124B1 (et) Toimeainena dotsetakseeli v?i selle hdraati sisaldava kompositsiooni kasutamine
HUP0301405A2 (hu) Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
DE60236541D1 (de) Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1
ATE468332T1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin- - yi)aminderivate
MXPA04001256A (es) Productos de combinacion de derivados de propanolamina aril substituidos con otros ingredientes activos y su uso.
HRP20040059B1 (hr) Tretman infekcije nokta s no
CO5580776A2 (es) Formulacion farmaceutica estable en solucion de oxaliplatino
NO20034204D0 (no) Farmasöytiske kombinasjoner til behandling av kreft
ATE396967T1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
ATE275393T1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
DE602005021770D1 (de) Indol-1-yl-essigsäurederivate
NO964433D0 (no) Farmasöytiske preparater på basis av derivater av taxanklassen
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
CY1106319T1 (el) Τοπικη θepαπεια στη μασταλγια
TR200302134T4 (tr) 2-metil-tiazolidin-2,4-dikarboksilik asit ve/veya bunun fizyolojik olarak uygun tuzlarının anti-kanser ajanları olarak kullanımı.
SE0000303D0 (sv) Novel compounds
EA200700979A1 (ru) Пероральные твердые лекарственные формы, содержащие низкую дозу эстрадиола
DE60023321D1 (de) Zusammensetzung gegen Coccidiose
MXPA04006269A (es) Composicion farmaceutica que comprende un inhibidor de alfa-glucosidasa y acido 4-oxobutanoico y uso de la misma para tratamiento de diabetes.
UA34406A (uk) Засіб для лікування розсіяного склерозу, спосіб лікування з його використанням та фармацевтична упаковка

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20101231

MM4A Lapsed by not paying the annual fees

Effective date: 20150829